Overview
Company Leadership Board of Directors Clinical Advisory Board Scientific Advisory Board Technical Advisory Board Investors Partners Pipeline Technology Overview Antibody-Drug Conjugate (ADC) Platform Publications News Press Releases In the News Careers Open Positions Novel ADC Pa
Funding
Amounts as reported; USD estimates shown only when they match- Latest round
- $62
- 2026-10 · Series C
- Records
- 1
- 1 month · all drawn
Data noteListed 1 funding record. Latest funding: $62 (Series C), Oct 23, 2026.
| Date | Funding estimate | Consideration (USD) | Investors | Sources |
|---|---|---|---|---|
| Oct 23, 2026 | $62 · Series C | — | The Column Group | 1 source Source ↗ |
Evidence Hexagon Bio raises $62 million Series COn 2026-10-23, according to fireround, Hexagon Bio raises $62 million in Series C funding. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| ||||
Select ▸ on a row to see its source brief and links.
Team, products & investors
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
真菌基因组学驱动的肿瘤与传染病药物发现公司 Company Leadership Board of Directors Clinical Advisory Board Scientific Advisory Board Technical Advisory Board Investors Partners Pipeline Technology Overview Antibody-Drug Conjugate (ADC) Platform Publications News Press Releases In the News Careers Open Positions Novel ADC Pa